{"id":251056,"date":"2022-03-15T00:00:00","date_gmt":"2022-03-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcg0124-biopharma-attention-deficit-hyperactivity-disorder-4\/"},"modified":"2026-03-31T10:40:20","modified_gmt":"2026-03-31T10:40:20","slug":"epidcg0124-biopharma-attention-deficit-hyperactivity-disorder-epidemiology-europe","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0124-biopharma-attention-deficit-hyperactivity-disorder-epidemiology-europe\/","title":{"rendered":"Attention-Deficit-Hyperactivity Disorder &#8211; Epidemiology &#8211; Europe"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of attention-deficit\/hyperactivity disorder (<abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of (<abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr>) for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr>, how many in each country in the developed world have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr>, how many in each country in the developed world are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 20 <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases of pediatric <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr> by <abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition\">DSM-IV<\/abbr> criteria.<\/li>\n<li>Total prevalent cases of adult <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr> by <abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition\">DSM-IV<\/abbr> criteria.<\/li>\n<li>Total prevalent cases of <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr> by <abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition\">DSM-5<\/abbr> criteria.<\/li>\n<li>Total prevalent cases of pediatric <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr> by subtype.<\/li>\n<li>Total prevalent cases of pediatric <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr> by comorbid oppositional defiant disorder (<abbr title=\"oppositional defiant disorder\">ODD<\/abbr>).<\/li>\n<li>Total prevalent cases of pediatric <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr> by symptoms.<\/li>\n<li>Total prevalent cases of adult <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr> by subtype.<\/li>\n<li>Prevalent cases of adult <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr> by diagnosis status.<\/li>\n<li>Diagnosed prevalent cases of adult <abbr title=\"attention-deficit\/hyperactivity disorder\">ADHD<\/abbr> by drug-treatment status.<\/li>\n<li>\u2026 and many more (details available on request).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251056","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-attention-deficit-hyperactivity-disorder","biopharma-therapy-areas-psychiatry","biopharma-product-epidemiology","biopharma-geography-europe","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251056\/revisions"}],"predecessor-version":[{"id":283500,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251056\/revisions\/283500"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}